<?xml version="1.0" ?>
<document id="dc180c51f54487e4bbbd129c1cc2e30deacd3181">
  <chunk id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c0" text="viruses Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus">
    <entity charOffset="34-43" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c0.e0" ontology_id="CHEBI_35222" text="Inhibitor" type="chemical"/>
  </chunk>
  <chunk id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1" text="The Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in 2012, and circulated worldwide with high mortality. The continual outbreaks of MERS-CoV highlight the importance of developing antiviral therapeutics. Here, we rationally designed a novel fusion inhibitor named MERS-five-helix bundle (MERS-5HB) derived from the six-helix bundle (MERS-6HB) which was formed by the process of membrane fusion. MERS-5HB consists of three copies of heptad repeat 1 (HR1) and two copies of heptad repeat 2 (HR2) while MERS-6HB includes three copies each of HR1 and HR2. As it lacks one HR2, MERS-5HB was expected to interact with viral HR2 to interrupt the fusion step. What we found was that MERS-5HB could bind to HR2P, a peptide derived from HR2, with a strong affinity value (K D ) of up to 0.24 nM. Subsequent assays indicated that MERS-5HB could inhibit pseudotyped MERS-CoV entry effectively with 50% inhibitory concentration (IC 50 ) of about 1 µM. In addition, MERS-5HB significantly inhibited spike (S) glycoprotein-mediated syncytial formation in a dose-dependent manner. Further biophysical characterization showed that MERS-5HB was a thermo-stable α-helical secondary structure. The inhibitory potency of MERS-5HB may provide an attractive basis for identification of a novel inhibitor against MERS-CoV, as a potential antiviral agent.">
    <entity charOffset="209-218" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e0" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="277-286" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e1" ontology_id="CHEBI_35222" text="inhibitor" type="chemical"/>
    <entity charOffset="735-742" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e2" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="1300-1309" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e3" ontology_id="CHEBI_35222" text="inhibitor" type="chemical"/>
    <entity charOffset="1343-1352" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e4" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e0" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e1" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p0" relation="true"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e0" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e2" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p1" relation="true"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e0" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e3" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p2" relation="true"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e1" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e2" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p3" relation="true"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e1" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e4" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p4" relation="true"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e2" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e3" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p5" relation="true"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e2" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e4" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p6" relation="true"/>
    <pair e1="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e3" e2="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.e4" id="dc180c51f54487e4bbbd129c1cc2e30deacd3181.c1.p7" relation="true"/>
  </chunk>
</document>
